Cannabidiol, a type of medicinal cannabis, may reduce severe behavioural problems in children and adolescents with an intellectual disability. A pilot study, led by the Murdoch Children’s Research Institute or MCRI, recorded a clinically significant change in participants’ irritability, aggression, self-injury and yelling. The intervention was also found to be safe and well-tolerated by most study participants.
The randomised controlled trial involved eight participants, aged eight to 16, years who took either cannabidiol or a placebo over eight weeks. Participants were recruited from paediatric clinics from both hospital and private paediatric practices.
Although the pilot study was not large enough to make definitive statements, the early findings strongly support a larger follow-up trial. Only a large scale randomised controlled trial can produce the definitive results necessary to drive changes in prescribing and clinical care guidelines. The researchers are planning a large study to definitively test the findings.
The researchers are also seeking funding for further research into the effectiveness of medicinal cannabis in children with developmental disorders such as autism and Tourette syndrome.
Associate Professor Daryl Efron, a clinician-scientist at MCRI who led the study, said this was the first investigation of cannabidiol to manage severe behavioural problems in children and adolescents with an intellectual disability. Most of the participants also had autism.
The study found the medication was generally well-tolerated and there were no serious side effects reported. All parents reported they would recommend the study to families with children with similar problems.
Efron said severe behavioural problems such as irritability, aggression and self-injury in children and adolescents with an intellectual disability were a major contributor to functional impairments, missed learning opportunities and reduced quality of life.
He said conventional psychotropic medications, including anti-psychotics and anti-depressants, were prescribed by Australian paediatricians for almost half of young people with an intellectual disability, despite limited evidence of their effectiveness.
Given how extremely difficult behavioural problems were to treat in these patients, new, safer interventions were needed to treat this highly vulnerable patient group, he said. “Current medications carry a high risk of side-effects, with vulnerable people with intellectual disability being less able to report side-effects,” he said. “Common side-effects of anti-psychotics, such as weight gain and metabolic syndrome, have huge health effects for a patient group already at increased risk of chronic illness.”
Cannabidiol is already being used increasingly to manage a range of medical and psychiatric conditions in adults and epilepsy in children.
Efron said there was intense interest from parents and physicians in medicinal cannabis as a treatment for severe behavioural problems in youth with an intellectual disability. “Parents of children with an intellectual disability and severe behavioural problems are increasingly asking paediatricians whether they can access medicinal cannabis for their child and some parents have reported giving unregulated cannabis products to their children,” he said.
“We are also finding many physicians feel unprepared to have these conversations with their patients.” Researchers from The Royal Children’s Hospital, the University of Melbourne and Monash University also contributed to the study.
Introduction: Severe Behavioural Problems (SBP) are a major contributor to morbidity in children with Intellectual Disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomized placebo‐controlled trial of cannabidiol to reduce SBP in children with ID.
Double‐blind, placebo‐controlled, two‐armed, parallel‐design, randomised controlled trial of cannabidiol in children aged 8 – 16 years with ID and SBP. Participants were randomized 1:1 to receive either 98% cannabidiol in oil (Tilray, Canada) or placebo orally for 8 weeks. The dose was up‐titrated over 9 days to 20mg/kg/day in two divided doses, with a maximum dose of 500mg twice/day. The feasibility and acceptability of all study components were assessed.
Eight children were randomised, and all completed the full study protocol. There were no Serious Adverse Events or drop‐outs. Protocol adherence for key study components was excellent: study visits 100%, medication adherence 100%, blood tests 92%, and questionnaire completion 88%. Parents reported a high degree of acceptability with the study design. All parents reported they would recommend the study to other families with children with similar problems. There was an efficacy signal in favour of active drug.
The findings suggest that the study protocol is feasible and acceptable to patients with ID and SBP and their families.
Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor and Katrina Williams.
Murdoch Children’s Research Institute material
British Journal of Clinical Pharmacology abstract